About Mestex
Mestex is a Healthcare company based in Basel (Switzerland) founded in 2014, and was acquired by Gruenenthal Group in April 2021. Therapy for osteoarthritis-related joint pain is developed. The company was acqui-hired. Its focus areas include Life Sciences, Orthopedics, Drugs and Osteoarthritis.
Company details
Mestex was founded in 2014 in Basel, Switzerland, within the biotechnology sector. Focus is placed on developing treatments for osteoarthritis-associated joint pain. The primary product, Lopain, is formulated with resiniferatoxin, an agonist targeting the TRPV1 channel to disrupt pain signal transmission. Administration occurs intra-articularly, addressing chronic joint conditions through targeted intervention. Operations center on advancing this therapeutic approach for clinical application.
- Headquarters Basel, Switzerland
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website mestex.ch
- Acquired by Gruenenthal Group (Apr 2021)
- Investors
- Acquired byGruenenthal Group
(Apr 2021)
Investors in Mestex
Mestex has secured backing from 1 investor. Prominent investors backing the company include Gruenenthal Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Specialty biopharmaceutical products are developed internationally by Gruenenthal Group. | 1946 | grunenthal.com | Aachen, Germany |
Investor details for Mestex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Mestex
2 dated milestones of Mestex across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Mestex is founded.
- Exit Acquired by Gruenenthal Group.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mestex
Complete news archive for Mestex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mestex
Mestex was founded in 2014.
Mestex is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Mestex was founded in 2014 in Basel, Switzerland, within the biotechnology sector. Focus is placed on developing treatments for osteoarthritis-associated joint pain. The primary product, Lopain, is formulated with resiniferatoxin, an agonist targeting the TRPV1 channel to disrupt pain signal transmission. Administration occurs intra-articularly, addressing chronic joint conditions through targeted intervention. Operations center on advancing this therapeutic approach for clinical application.
Mestex has 1 investor. Key investors include Gruenenthal Group.
Yes. Mestex was acquired by Gruenenthal Group in April 2021.